Astrocytes mapped as brain networks & Gene therapy for congenital deafness - News (Apr 23, 2026)

We’ll start in neuroscience, where researchers say they’ve uncovered a hidden layer of brain organization. A new mouse-brain map traces extensive, long-range networks formed by astrocytes—the star-shaped cells often described as the brain’s support crew. Using a gene-therapy-style molecular “stamp” to tag what passes through astrocyte connections, the team produced a whole-brain 3D atlas showing chains that can link distant regions, even bridging the two hemispheres. They also report these networks are flexible, reshaping after sensory deprivation. The big takeaway: astrocyte communication may not be just local housekeeping—it could be a brain-wide system with implications for how we think about disorders that don’t fit neatly into a neuron-only story.

Staying with gene-based medicine, a Nature paper is reporting longer-term results from a multi-centre study testing an AAV1 gene therapy for DFNB9, a form of congenital deafness tied to the OTOF gene. The key question has been durability: do hearing gains last? Participants were followed for as long as two and a half years, with repeated objective and behavioral hearing tests tracking whether improvements held up. The extended analyses also compare outcomes by dose and age, and examine whether baseline cochlear measurements might predict who benefits most. On the safety side, the study tracked immune responses to the viral vector and monitored for shedding. It’s an important step beyond earlier, smaller reports—because for inner-ear gene therapy, long-term stability and real-world delivery matter as much as the initial breakthrough.

And another public-health watch item: the UK has begun vaccinating the first volunteers in a large clinical trial of an mRNA vaccine aimed at the H5N1 bird flu strain. Officials still say the risk to the general public is low, since most human cases so far have involved close contact with infected animals. But scientists are watching the virus’s evolution closely, and the trial is designed to answer a practical question: can an mRNA shot produce a strong immune response safely, especially in higher-risk groups like poultry workers and older adults? If it works, the UK could manufacture quickly at Moderna’s Harwell site—highlighting one reason mRNA remains attractive for outbreaks where older vaccine production methods can stumble.

From vaccines to cancer research: at the AACR 2026 meeting, one of the most closely watched updates has been new clinical results for Revolution Medicines’ KRAS-targeting drug, daraxonrasib. Earlier data suggested the pill more than doubled survival compared with chemotherapy for patients with second-line pancreatic cancer—roughly a six-month improvement in median survival for a disease notorious for giving patients very little time. The reason this is drawing attention is simple: KRAS has long been treated as one of the toughest targets in oncology, and pancreatic cancer has been even tougher. Even incremental progress can shift treatment expectations—and guide what drug developers try next.

Another striking story in gene therapy this week comes from the NHS in England. A six-year-old girl, Saffie Sandford from Stevenage, has had her eyesight restored after receiving Luxturna for a rare inherited condition called Leber’s Congenital Amaurosis linked to the RPE65 gene. Her family describes everyday changes—moving more confidently, better peripheral vision, and easier time at school. Clinicians at Great Ormond Street Hospital and researchers at University College London have also pointed to evidence that treatment in young children may strengthen visual pathways. The broader significance is that early genetic diagnosis can be the difference between a narrow eligibility window and a missed opportunity.

Now to the tech world, where the pace of AI adoption inside big companies keeps accelerating. Google says about three-quarters of its newly created code is now generated by AI and then reviewed by human engineers. That’s a steep jump from roughly a quarter in late 2024. CEO Sundar Pichai tied it to more “agentic” workflows—basically, AI systems taking on bigger chunks of work with less step-by-step prompting. Google also appears to be hardwiring AI usage into workplace expectations, with some employees reporting AI-related goals in performance reviews. It’s a milestone that raises a new baseline for productivity—and also new questions about training, oversight, and what software engineering looks like when writing code becomes less of the job than judging it.

In geopolitics, Japan has approved new guidelines that scrap its long-standing ban on exporting lethal weapons—a major departure from decades of postwar restraint. Prime Minister Sanae Takaichi’s Cabinet framed the move as necessary to strengthen national security and revive a domestic defense industry, amid concerns about China, North Korea, and Russia. The rules now open the door to exports of more serious military hardware, though Japan says sales will be limited to a set of partner countries with security agreements, require high-level approval, and include end-use monitoring. Allies like Australia and the United States have welcomed the shift, while China condemned it and critics at home argue it clashes with Japan’s pacifist constitution. The bigger picture is Japan moving toward a more forward security role—and changing the regional calculus as it does.

On international justice, appeals judges at the International Criminal Court have ruled the ICC has jurisdiction to try former Philippine president Rodrigo Duterte, rejecting the argument that the case should be dismissed because the Philippines withdrew from the court in 2018. The judges said the court can proceed because the preliminary examination began before the withdrawal. Duterte, now 81, has been detained in The Hague since his arrest in March 2025. Prosecutors accuse him of organizing and supporting death squads linked to thousands of killings during the anti-drug campaign; he has argued the crackdown was lawful. For victims’ families, the decision is being read as a step toward accountability—and for other leaders, it’s a reminder that leaving the ICC doesn’t necessarily erase exposure for alleged crimes committed while a country was still under its reach.

Finally, a look at malaria—where urgency is growing as Africa falls behind the African Union’s 2030 elimination goals. Scientists working with the Target Malaria consortium are testing whether gene drive technology could eventually help reduce malaria transmission by altering mosquito populations. It’s still early-stage and contained to tightly controlled lab research, with no releases in Africa. But the push reflects a tough reality: funding gaps, insecticide resistance, climate pressures, and fragile health systems are raising fears of a resurgence. With hundreds of millions of cases and more than half a million deaths recorded in 2024, researchers argue new tools may be needed—while also acknowledging that community consent, regulation, and long-term governance would be as crucial as the science itself.